Edwards, Natalie C.; Rupnow, Marcia F.T.; Pashos, Chris L. - In: PharmacoEconomics 23 (2005) 3, pp. 299-314
Background: Schizophrenia is a devastating and costly illness that affects 1% of the population in the US. Effective pharmacological therapies are available but suboptimal patient adherence to either acute or long-term therapeutic regimens reduces their effectiveness. The availability of a...